Antipsychotic drugs and QT interval prolongation

被引:83
|
作者
Zareba, W [1 ]
Lin, DA [1 ]
机构
[1] Univ Rochester, Med Ctr, Heart Res Follow Up Program, Dept Med,Cardiol Unit, Rochester, NY 14642 USA
关键词
QTc prolongation; antipsychotic drugs; torsades de pointes;
D O I
10.1023/A:1024122706337
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
The QTc prolongation by antipsychotic drugs is of major concern, especially in light of the data indicating an increased risk of sudden death in psychiatric patients taking these drugs. Sudden death in psychiatric patients could be partially attributed to drug-induced torsades de pointes and for this reason careful evaluation of QTc prolonging properties of antipsychotic drugs is needed. Antipsychotic drugs prolong QT interval usually by blocking the potassium I-Kr current. Improved understanding of ion channel structure and kinetics and its role in repolarization has tremendous impact on understanding of the mechanisms of drug-induced QT prolongation and torsades de pointes. Proarrhythmia caused by a QT-prolonging drug occurs infrequently, and usually multiple factors need to operate to precipitate such an event including a combination of two or more drugs affecting the same pathway, hypokalemia, and possibly genetic predisposition. Currently prescribed antipsychotics might cause QT prolongation ranging from 4-6 ms for haloperidol and olanzapine to 35 ms for thioridazine. The response of a patient to a drug is very individual and therefore an individualized system of drug administration and monitoring needs to be developed which takes into account baseline QTc duration and its changes after a drug was introduced. A systematic approach while stratifying psychiatric patients as those with short QTc (QTc less than or equal to 0.41 sec), borderline QTc QTC = 0.42-0.44 sec), and prolonged QTc (0.45 sec) is being proposed to improve the safety of administering antipsychotic drugs and to decrease the risk of drug-related sudden death in psychiatric patients.
引用
收藏
页码:291 / 306
页数:16
相关论文
共 50 条
  • [31] QT interval and dispersion in very young children treated with antipsychotic drugs
    Nahshoni, E.
    Spitzer, S.
    Berant, M.
    Shoval, G.
    Zalsman, G.
    Weizman, A.
    EUROPEAN PSYCHIATRY, 2007, 22 : S162 - S162
  • [32] Aging effects on QT interval: Implications for cardiac safety of antipsychotic drugs
    Rabkin, Simon W.
    JOURNAL OF GERIATRIC CARDIOLOGY, 2014, 11 (01) : 20 - 25
  • [33] The real-world incidence of severe QT prolongation in patients taking antipsychotic drugs
    TeBay, Clifford
    Vandenberg, Jamie I.
    HEART RHYTHM, 2024, 21 (03) : 329 - 330
  • [34] QT interval prolongation by noncardiovascular drugs: issues and solutions for novel drug development
    Crumb, W
    Cavero, I
    PHARMACEUTICAL SCIENCE & TECHNOLOGY TODAY, 1999, 2 (07): : 270 - 280
  • [35] QT Interval Prolongation: Preclinical and Clinical Testing Arrhythmogenesis in Drugs and Regulatory Implications
    Giorgi, Mariano A.
    Bolanos, Ricardo
    Daniel Gonzalez, Claudio
    Di Girolamo, Guillermo
    CURRENT DRUG SAFETY, 2010, 5 (01) : 54 - 57
  • [36] Other Drugs Acting on Nervous System Associated with QT-Interval Prolongation
    Alberto Keller, Guillermo
    Ponte, Marcelo L.
    Di Girolamo, Guillermo
    CURRENT DRUG SAFETY, 2010, 5 (01) : 105 - 111
  • [37] QT interval prolongation: And the beat goes on
    Jalaie, M
    Holsworth, DD
    MINI-REVIEWS IN MEDICINAL CHEMISTRY, 2005, 5 (12) : 1083 - 1091
  • [39] QT Interval Prolongation in Cirrhotic Cardiomyopathy
    Tadelle, Amanuel
    RESEARCH REPORTS IN CLINICAL CARDIOLOGY, 2022, 13 : 55 - 61
  • [40] Safety pharmacology and prolongation of the QT interval
    Cavero, Icilio
    Yan, Gan-Xin
    Lux, Robert
    Steinhoff, Uwe
    JOURNAL OF ELECTROCARDIOLOGY, 2007, 40 (01) : S58 - S61